市場調查報告書
商品編碼
1467891
消化性潰瘍藥物市場依產品類型(質子幫浦抑制劑、鉀競爭性酸阻斷劑、制酸劑、H2拮抗劑、抗生素、潰瘍保護劑)、潰瘍類型、配銷通路和地區2024-2032年Peptic Ulcer Drugs Market by Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker, Antacids, H2-Antagonists, Antibiotics, Ulcer protective), Ulcer Type, Distribution Channel, and Region 2024-2032 |
IMARC Group年全球消化性潰瘍藥物市場規模達48億美元。消化性潰瘍的盛行率不斷增加,尤其是在老年族群中,以及消費者傾向於使用各種藥物而不是侵入性手術,這是推動市場發展的一些關鍵因素。
消化性潰瘍或十二指腸潰瘍是一種開放性潰瘍,逐漸發展並引發胃、小腸和下食道內壁的缺陷。它們通常是由於發炎、放射治療、頻繁口服和注射阿斯匹靈以及抗發炎藥物引起的。如果消化性潰瘍未及時治療,可能會引起中上身劇烈疼痛、體重減輕、內出血和嚴重失血,需要住院治療。目前,他們可以用多種藥物類型進行治療,包括質子幫浦抑制劑(PPI)、H2拮抗劑、抗生素、鉀競爭性酸阻斷劑(P-CAB)、制酸劑和潰瘍保護劑。這些藥物可以減輕身體疼痛,提供更多的癒合時間,最大限度地減少胃酸分泌,抵抗細菌感染,並保護胃免受消化液的侵害。因此,消化性潰瘍藥物被醫療保健從業人員廣泛用於治療胃炎、胃食道逆流(GERD)和十二指腸潰瘍。
消化性潰瘍的盛行率不斷增加,特別是在老年族群中,是推動市場成長的關鍵因素之一。此外,不健康的生活習慣和胃癌發病率的上升,導致越來越多的人患有消化性潰瘍。再加上消費者對各種消化性潰瘍治療藥物而非侵入性手術的傾向不斷變化,這反過來又促進了市場的成長。與此一致的是,與外科手術相比,幾種類固醇抗發炎藥物具有微創性、更實惠,並且可以在確保減少失血的同時實現更快的恢復。此外,消化性潰瘍藥物的持續批准以及政府對製藥公司的藥物配方投資也支持了市場的成長。這進一步受到持續進行新藥形成臨床試驗以克服併發症和市面上現有藥物無效的影響。此外,消費者越來越意識到經濟高效的消化性潰瘍藥物的好處及其在多個分銷管道上的便利性,這有利於市場的成長。用於執行診斷和法醫操作的基於人工智慧(AI)的病理測試技術的出現也推動了市場的成長。其他因素,例如為提高產品功效而進行的廣泛研發(R&D)活動以及增加用於開發治療消化性潰瘍的非處方(OTC)藥物的投資,正在對市場成長產生積極影響。
The global peptic ulcer drugs market size reached US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.1 Billion by 2032, exhibiting a growth rate (CAGR) of 2.65% during 2024-2032. The increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various medications over invasive surgeries represent some of the key factors driving the market.
Peptic ulcers, or duodenal ulcers, are open sore that gradually develops and triggers defects in the lining of the stomach, small intestine, and lower esophagus. They are usually caused due to inflammation, radiation therapy, frequent oral and injectable administration of aspirins, and anti-inflammatory drugs. If peptic ulcers are left untreated, they might initiate severe pain in the mid- or upper-body parts, weight loss, internal bleeding, and severe blood loss, which require hospitalization. Currently, they can be treated with various drug types, including proton pump inhibitors (PPI), H2 antagonists, antibiotics, potassium-competitive acid blockers (P-CAB), antacids, and ulcer protectives. These medications reduce body aches, provide more time to heal, minimize acid secretion, offer resistance against bacterial infections, and protect the stomach from digestive juices. As a result, peptic ulcer drugs are extensively utilized by healthcare practitioners for the treatment of gastritis, gastroesophageal reflux disease (GERD), and duodenal ulcers.
The increasing prevalence of peptic ulcers, especially amongst the geriatric population, represents one of the key factors driving the market growth. Moreover, unhealthy lifestyle habits and rising instances of stomach cancer, is resulting in the growing number of individuals suffering from peptic ulcers. This, along with the shifting consumer inclination towards various peptic ulcer-curing drugs over invasive surgeries, which, in turn, is contributing to the market growth. In line with this, as compared to surgical procedures, several steroidal anti-inflammatory medications are minimally invasive, more affordable, and enable faster recovery while ensuring reduced blood loss. Additionally, the ongoing approvals of peptic ulcer drugs and several government investments in pharmaceutical companies for the formulation of medications are supporting the market growth. This is further influenced by the continuous conduction of clinical trials for new drug formation to overcome complications and the ineffectiveness of present drugs in the market. Moreover, the increasing consumer awareness regarding the benefits of cost-effective peptic ulcer drugs and their easy availability across multiple distribution channels is favoring the market growth. The advent of artificial intelligence (AI)-based pathology testing technology to perform diagnostic and forensic operations is also propelling the market growth. Other factors, such as extensive research and development (R&D) activities to enhance product efficacy and the increasing investments in the development of the over the counter (OTC) medications for treating peptic ulcers, are positively impacting the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global peptic ulcer drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on product type, ulcer type, and distribution channel.
Proton Pump Inhibitors
Potassium-Competitive Acid Blocker (P-CAB)
Antacids
H2-Antagonists
Antibiotics
Ulcer protective
The report has also provided a detailed breakup and analysis of the peptic ulcer drugs market based on the product type. This includes proton pump inhibitors, potassium-competitive acid blocker (P-CAB), antacids, H2-antagonists, antibiotics, and ulcer protective. According to the report, antibiotics represented the largest segment.
Gastric Ulcer
Duodenal Ulcer
Others
A detailed breakup and analysis of the peptic ulcer drugs market based on the ulcer type has also been provided in the report. This includes gastric ulcer, duodenal ulcer, and others. According to the report, duodenal ulcer accounted for the largest market share.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The report has also provided a detailed breakup and analysis of the peptic ulcer drugs market based on the distribution channel. This includes hospital, retail and online pharmacies. According to the report, hospital pharmacies represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for peptic ulcer drugs. Some of the factors driving the North America peptic ulcer drugs market included the increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various peptic ulcer curing drugs over invasive surgeries and the fueling need for over-the-counter (OTC) medications in the healthcare sector.
The report has also provided a comprehensive analysis of the competitive landscape in the global peptic ulcer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novitium Pharma LLC, Pfizer Inc., PharmaKing Co. Ltd., RedHill Biopharma Ltd, Viatris Inc., Yuhan Corporation, Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.